We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.
Main Menu

Professor Sue Eccles

Team leader

The alt text
Professor Sue Eccles is researching the cellular processes behind tumour progression with the potential of developing new drug targets. Her research has led to the development of new 3D models which are used to investigate cancer progression and response to treatment. Team: Tumour Biology and Metastasis

T 0208 722 4210


Professor Sue Eccles leads the Tumour Biology and Metastasis Team in the Division of Cancer Therapeutics. As a Professor of Experimental Cancer Therapeutics, she investigates the cellular processes responsible for tumour progression, with the aim of discovering new therapeutic targets.

Her research involves the development of preclinical models of glioma, breast and prostate cancers, and squamous carcinomas of the head and neck. Through a strong collaboration with the Paediatric Oncology group at The Royal Marsden NHS Foundation Trust, Professor Eccles has also developed models of childhood cancers that are being used in paediatric drug development.

Working closely with colleagues in magnetic resonance imaging (MRI), Professor Eccles’s team then use these tumour models to test the effects of new drugs targeting cancers, and to gain an understanding of the mechanisms by which cancer becomes resistant to treatment.

Her translational research has contributed to the nomination of several new anti-cancer agents that are now in preclinical development or clinical trial, including Hsp90, PI3K and CHK1 inhibitors.

One current focus of Professor Eccles’s lab is the development of high-throughput screening of three-dimensional cultures of cancer cells. These spherical models of cancer more closely match tumour biology than two-dimensional cell cultures, and Professor Eccles aims to further develop their use in drug design.